Expression of human factors CD81, claudin-1, scavenger receptor, and occludin in mouse hepatocytes does not confer susceptibility to HCV entry

Biomedical Research

Volumn 32, Issue 2, 2011, Pages 143-150

  Hikosaka, Keisuke ^a   Noritake, Hidenao ^a   Kimura, Wataru ^a   Sultana, Nishat ^a   Sharkar, Mohammad T K ^a   Tagawa, Yoh Ichi ^b   Uezato, Tadayoshi ^a   Kobayashi, Yoshimasa ^a   Wakita, Takaji ^c   Miura, Naoyuki ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; CLAUDIN 1; GLYCOPROTEIN E1; GLYCOPROTEIN E2; OCCLUDIN; SCAVENGER RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUSION; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; LIVER CELL; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; TRANSGENIC MOUSE; VIRUS DETECTION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS PARTICLE; WILD TYPE;

ANIMALS; ANTIGENS, CD; CELL FUSION; CELLS, CULTURED; FEMALE; GENE EXPRESSION; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; LEUKEMIA VIRUS, MURINE; LIVER; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; RECEPTORS, VIRUS; SCAVENGER RECEPTORS, CLASS B; VIRION; VIRUS INTERNALIZATION;

HEPATITIS C VIRUS; MUS; MUS MUSCULUS;

EID: 79957684220     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.32.143     Document Type: Article

References (28)

1. Bartosch B, Dubuisson J and Cosset F-L (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197, 633-642.
2. Benedicto I, Molina-Jiménez F, Bartosch B, Cosset F-L, Lavillette D, Prieto J, Moreno-Otero R, Valenzuela-Fernández A, Aldabe R, López-Cabrera M and Majano PL (2009) The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol 83, 8012-8020.
3. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C and Rouillé Y (2006) Hepatitis C virus en-try depends on clathrin-mediated endocytosis. J Virol 80, 6964-6972.
4. Calzolari A, Raggi C, Deaglio S, Sposi NM, Stafsnes M, Fecchi K, Parolini I, Malavasi F, Peschle C, Sargiacomo M and Testa U (2006) TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 119, 4486-4498.
5. Carloni V, Mazzocca A and Ravichandran KS (2004) Tetraspanin CD81 is linked to ERK/MAPKinase signaling by Shc in liver tumor cells. Oncogene 23, 1566-1574.
6. Codran A, Royer C, Jaeck D, Bastien-Valle M, Baumert TF, Kieny MP, Pereira CA and Martin J-P (2006) Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol 87, 2583-2593.
7. Coyne CB, Shen L, Turner JR and Bergelson JM (2007) Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host Microbe 2, 181-192.
8. Evans MJ, Hahn T von, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD and Rice CM (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801-805.
9. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S and McKeating JA (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73, 6235-6244.
10. Fukumoto K, Wang B, Hikosaka K, Noritake H, Shibata K, Inoue H, Suzuki A, Inaba K, Sakaguchi T, Suzuki S, Konno H and Miura N (2008) Live imaging by time-lapse microscopy can more clearly evaluate the anti-apoptotic state of primary hepatocytes isolated from the drs knockout mouse. Akita J Med 35, 231-237.
11. Grove J, Huby T, Stamataki Z, Vanwolleghem T, Meuleman P, Farquhar M, Schwarz A, Moreau M, Owen JS, Leroux-Roels G, Balfe P and McKeating JA (2007) Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol 81, 3162-3169.
12. Guan X, Peng J-R, Yuan L, Wang H, Wei Y-H and Leng X-S (2004) A novel, rapid strategy to form dendritomas from human dendritic cells and hepatocellular carcinoma cell line HCCLM3 cells using mature dendritic cells derived from human peripheral blood CD14+ monocytes within 48 hours of in vitro culture. World J Gastroenterol 10, 3564-3568.
13. Harris HJ, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, Jennings A, Hu K, Yuan F, Deng H, Hubscher SG, Han JH, Balfe P and McKeating JA (2008) CD81 and claudin 1 core-ceptor association: role in hepatitis C virus entry. J Virol 82, 5007-5020.
14. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM and McKeating JA (2003) Hepatitis C virus glyco-proteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 100, 7271-7276.
15. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset F-L, McKeating JA, Schuster C and Baumert TF (2010) Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51, 1144-1157.
16. Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, Abrignani S and Uematsu Y (2002) Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 304, 187-196.
17. Meertens L, Bertaux C and Dragic T (2006) Hepatitis C vi-rus entry requires a critical postinternalization step and delivery to early endosomes via clathrincoated vesicles. J Virol 80, 11571-11578.
18. Meola A, Sbardellati A, Bruni Ercole B, Cerretani M, Pezzanera M, Ceccacci A, Vitelli A, Levy S, Nicosia A, Traboni C, McKeating J and Scarselli E (2000) Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol 74, 5933-5938.
19. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL and Kneteman NM (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7, 927-933.
20. Patel AH, Wood J, Penin F, Dubuisson J and McKeating JA (2000) Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol 81, 2873-2883.
21. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G and Abrignani S (1998) Binding of hepatitis C virus to CD81. Science 282, 938-941.
22. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, Jong YP de and Rice CM (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882-886.
23. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R and Vitelli A (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21, 5017-5025.
24. Slater-Handshy T, Droll DA, Fan X, Di Bisceglie AM and Chambers TJ (2004) HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression K. Hikosaka et al. and processing. Virology 319, 36-48.
25. Tilghman SM and Belayew A (1982) Transcriptional control of the murine albumin/alpha-fetoprotein locus during development. Proc Natl Acad Sci USA 79, 5254-5257.
26. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD,McKeating JA and Rice CM (2006) Time and temperature-dependent activation of hepatitis C virus for low-pH-trig-gered entry. J Virol 80, 1734-1741.
27. Wakita T (2009) Isolation of JFH-1 strain and development of an HCV infection system. Methods Mol Biol 510, 305-327.
28. Yamamoto H, Quinn G, Asari A, Yamanokuchi H, Teratani T, Terada M and Ochiya T (2003) Differentiation of embryonic stem cells into hepatocytes: biological functions and thera-peutic application. Hepatology 37, 983-993.